UBS AM: Teva Pharmaceutical Industries TEVA Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 198 M | Compra |
4,999,125
+1,166,660
| +30% | +USD 41.7 M | 0.03% | 407 |
|
|
2026
Q2 | USD 130 M | Compra |
3,832,465
+3,775,221
| +6,595% | +USD 126 M | 0.02% | 459 |
|
|
2026
Q1 | USD 1.72 M | Compra |
57,244
+51,590
| +912% | +USD 1.66 M | ﹤0.01% | 2110 |
|
|
2025
Q4 | USD 176 k | Venta |
5,654
-49,544
| -90% | -USD 1.22 M | ﹤0.01% | 2471 |
|
|
2025
Q3 | USD 1.12 M | Venta |
55,198
-4,616,537
| -99% | -USD 81.1 M | ﹤0.01% | 1972 |
|
|
2025
Q2 | USD 78.3 M | Compra |
4,671,735
+1,134,411
| +32% | +USD 18.3 M | 0.02% | 586 |
|
|
2025
Q1 | USD 54.4 M | Compra |
3,537,324
+196,261
| +6% | +USD 3.51 M | 0.01% | 671 |
|
|
2024
Q4 | USD 73.6 M | Venta |
3,341,063
-36,454
| -1% | -USD 663 k | 0.02% | 580 |
|
|
2024
Q3 | USD 60.9 M | Compra |
3,377,517
+2,376,668
| +237% | +USD 41.6 M | 0.02% | 633 |
|
|
2024
Q2 | USD 16.3 M | Venta |
1,000,849
-1,222,615
| -55% | -USD 18.8 M | ﹤0.01% | 941 |
|
|
2024
Q1 | USD 31.4 M | Venta |
2,223,464
-39,486
| -2% | -USD 498 k | 0.01% | 688 |
|
|
2023
Q4 | USD 23.6 M | Venta |
2,262,950
-27,401
| -1% | -USD 256 k | 0.01% | 735 |
|
|
2023
Q3 | USD 23.4 M | Compra |
2,290,351
+371,868
| +19% | +USD 3.46 M | 0.01% | 734 |
|
|
2023
Q2 | USD 17 M | Sin cambios |
1,918,483
| – | – | 0.01% | 807 |
|
|
2023
Q1 | USD 17 M | Compra |
1,918,483
+88,077
| +5% | +USD 871 k | 0.01% | 807 |
|
|
2022
Q4 | USD 16.7 M | Compra |
1,830,406
+153,181
| +9% | +USD 1.34 M | 0.01% | 798 |
|
|
2022
Q3 | USD 13.5 M | Venta |
1,677,225
-128,515
| -7% | -USD 1.14 M | 0.01% | 866 |
|
|
2022
Q2 | USD 13.6 M | Compra |
1,805,740
+5,980
| +0.3% | +USD 52.1 k | 0.01% | 849 |
|
|
2022
Q1 | USD 16.9 M | Venta |
1,799,760
-90,715
| -5% | -USD 757 k | 0.01% | 887 |
|
|
2021
Q4 | USD 15.1 M | Venta |
1,890,475
-23,365
| -1% | -USD 211 k | 0.01% | 980 |
|
|
2021
Q3 | USD 18.6 M | Compra |
1,913,840
+130,872
| +7% | +USD 1.23 M | 0.01% | 888 |
|
|
2021
Q2 | USD 17.7 M | Venta |
1,782,968
-88,857
| -5% | -USD 941 k | 0.01% | 920 |
|
|
2021
Q1 | USD 21.6 M | Venta |
1,871,825
-60,855
| -3% | -USD 698 k | 0.01% | 845 |
|
|
2020
Q4 | USD 18.7 M | Venta |
1,932,680
-17,610
| -0.9% | -USD 169 k | 0.01% | 864 |
|
|
2020
Q3 | USD 17.6 M | Compra |
1,950,290
+14,913
| +0.8% | +USD 158 k | 0.01% | 810 |
|
|
2020
Q2 | USD 23.9 M | Venta |
1,935,377
-57,980
| -3% | -USD 656 k | 0.01% | 693 |
|
|
2020
Q1 | USD 17.9 M | Compra |
1,993,357
+91,645
| +5% | +USD 939 k | 0.01% | 701 |
|
|
2019
Q4 | USD 18.6 M | Compra |
1,901,712
+177,129
| +10% | +USD 1.58 M | 0.01% | 794 |
|
|
2019
Q3 | USD 11.9 M | Compra |
1,724,583
+190,023
| +12% | +USD 1.46 M | 0.01% | 903 |
|
|
2019
Q2 | USD 14.2 M | Venta |
1,534,560
-302,680
| -16% | -USD 3.65 M | 0.01% | 851 |
|
|
2019
Q1 | USD 28.8 M | Venta |
1,837,240
-568,823
| -24% | -USD 10 M | 0.02% | 658 |
|
|
2018
Q4 | USD 37.1 M | Compra |
2,406,063
+984,975
| +69% | +USD 20.2 M | 0.03% | 544 |
|
|
2018
Q3 | USD 30.6 M | Venta |
1,421,088
-13,123
| -0.9% | -USD 305 k | 0.02% | 640 |
|
|
2018
Q2 | USD 34.9 M | Compra |
1,434,211
+51,428
| +4% | +USD 1.05 M | 0.03% | 623 |
|
|
2018
Q1 | USD 23.6 M | Venta |
1,382,783
-661
| -0% | -USD 12.9 k | 0.02% | 728 |
|
|
2017
Q4 | USD 26.2 M | Compra |
1,383,444
+13,930
| +1% | +USD 210 k | 0.02% | 672 |
|
|
2017
Q3 | USD 24.1 M | Compra |
1,369,514
+10,565
| +0.8% | +USD 238 k | 0.02% | 695 |
|
|
2017
Q2 | USD 45.1 M | Venta |
1,358,949
-6,213
| -0.5% | -USD 192 k | 0.04% | 447 |
|
|
2017
Q1 | USD 43.8 M | Venta |
1,365,162
-639,598
| -32% | -USD 21.8 M | 0.04% | 446 |
|
|
2016
Q4 | USD 72.7 M | Compra |
2,004,760
+1,205,253
| +151% | +USD 48.1 M | 0.08% | 266 |
|
|
2016
Q3 | USD 36.8 M | Venta |
799,507
-1,898,185
| -70% | -USD 99 M | 0.04% | 470 |
|
|
2016
Q2 | USD 136 M | Venta |
2,697,692
-317,981
| -11% | -USD 16.9 M | 0.15% | 156 |
|
|
2016
Q1 | USD 161 M | Compra |
3,015,673
+624,629
| +26% | +USD 36.6 M | 0.19% | 120 |
|
|
2015
Q4 | USD 157 M | Compra |
2,391,044
+583,167
| +32% | +USD 36 M | 0.18% | 134 |
|
|
2015
Q3 | USD 102 M | Compra |
1,807,877
+473,814
| +36% | +USD 30.7 M | 0.11% | 206 |
|
|
2015
Q2 | USD 78.8 M | Venta |
1,334,063
-216,121
| -14% | -USD 13.3 M | 0.08% | 284 |
|
|
2015
Q1 | USD 96.6 M | Compra |
1,550,184
+940,062
| +154% | +USD 54.7 M | 0.09% | 245 |
|
|
2014
Q4 | USD 35.1 M | Venta |
610,122
-13,864
| -2% | -USD 772 k | 0.03% | 534 |
|
|
2014
Q3 | USD 33.5 M | Venta |
623,986
-192,554
| -24% | -USD 10.2 M | 0.03% | 540 |
|
|
2014
Q2 | USD 42.8 M | Venta |
816,540
-37,079
| -4% | -USD 1.9 M | 0.04% | 456 |
|
|
2014
Q1 | USD 45.1 M | Venta |
853,619
-251,636
| -23% | -USD 11.6 M | 0.05% | 406 |
|
|
2013
Q4 | USD 44.3 M | Venta |
1,105,255
-979,907
| -47% | -USD 38.6 M | 0.05% | 380 |
|
|
2013
Q3 | USD 78.8 M | Compra |
2,085,162
+213,283
| +11% | +USD 8.32 M | 0.1% | 234 |
|
|
2013
Q2 | USD 73.4 M | Compra |
+1,871,879
| Nuevas | +USD 72.9 M | 0.09% | 241 |
|
Otros fondos que tienen TEVA en su portafolio
Posición de UBS AM en TEVA: resumen de T3 2026
UBS AM aumentó su participación en Teva Pharmaceutical Industries (TEVA) en 30% durante T3 2026, al comprar aproximadamente USD 41.7 M y elevar la posición a 4,999,125 acciones con un valor de USD 198 M. La posición representa 0.03% del portafolio y ocupa el puesto #407.
UBS AM reportó por primera vez una posición en TEVA en T2 2013 y desde entonces la ha mantenido en 54 trimestres. Al cierre de T3 2026, 598 fondos que sigue Wall St. Rank mantienen una posición en TEVA.
- Al cierre de T3 2026, UBS AM tenía 4,999,125 acciones de Teva Pharmaceutical Industries con un valor de USD 198 M.
- UBS AM compró 1,166,660 acciones de Teva Pharmaceutical Industries en T3 2026, por un monto estimado de USD 41.7 M.
- Teva Pharmaceutical Industries representó el 0.03% del portafolio de UBS AM en T3 2026 y fue su posición número 407.
- UBS AM reportó por primera vez una posición en Teva Pharmaceutical Industries en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- Al cierre de T3 2026, 598 fondos que sigue Wall St. Rank tenían Teva Pharmaceutical Industries en su portafolio.
Según el informe 13F de UBS AM correspondiente a T3 2026, presentado el 16 nov 2026.